Printer Friendly

SPAIN TAKES ACTION ON HALCION

 SPAIN TAKES ACTION ON HALCION
 KALAMAZOO, Mich., Jan. 9 /PRNewswire/ -- The Ministry of Health in


Spain advised Upjohn today that it is suspending the 0.25 mg tablet of Halcion Tablets from the Spanish market for six months. The product remains on the market in the form of the 0.125 mg tablet, and dosage recommendations are unchanged.
 Upjohn Chairman and Chief Executive Officer Theodore Cooper, M.D., Ph.D., said, "We don't believe this action is based on good scientific or medical evidence. Halcion is a safe and effective medication when it's used as recommended."
 Upjohn will appeal this decision.
 The Upjohn Company (NYSE: UPJ) is a worldwide, research-based provider of human health care products, animal health products, agronomic and vegetable seeds and specialty chemicals. Headquartered in Kalamazoo, the company has been dedicated to improving health and nutrition for more than a century.
 -0- 1/9/92
 /CONTACT: Kaye Bennett of The Upjohn Company, 616-323-4224/
 (UPJ) CO: The Upjohn Company ST: Michigan IN: MTC SU:


SB -- DE011 -- 8143 01/09/92 10:33 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 9, 1992
Words:175
Previous Article:IBM PS/1 386 SX NOVELL CERTIFIED; SMALL BUSINESS CAPABILITIES ENHANCED
Next Article:FORD DECLARES DIVIDENDS
Topics:


Related Articles
UPJOHN ANNOUNCES NEW U.S. PACKAGING AND LABELING FOR HALCION
UPJOHN ENDORSES EC DECISION ON HALCION
UPJOHN ENDORSES EC DECISION ON HALCION
UPJOHN RESPONSE TO HALCION TV CHARGES
UPJOHN APPEALS HALCION SUSPENSION TO U.K. MEDICINES COMMISSION
UPJOHN WINS HALCION CASE
UPJOHN RESPONDS TO WOLFE FDA LETTER
PRESCRIPTION PROGRAM LIMITS REIMBURSEMENT FOR RESTORIL
SPORANOX SETS RECORDS FOR CONSUMER RESPONSE AND PRESCRIPTIONS FOR TREATMENT OF TOENAIL FUNGUS
PHARMACIA & UPJOHN RESPONDS TO FDA HALCION REPORT

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters